Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J, Adnane J, Longy M, Katsaros D, Sismondi P, Gaudray P
Laboratory of Molecular Biology, Institut de Génétique et Biologie Cellulaire, Montpellier, France.
Genes Chromosomes Cancer. 1993 Aug;7(4):219-26. doi: 10.1002/gcc.2870070407.
Several chromosomal regions are found to be consistently amplified in human breast cancers. For two of these regions, 8p12 and 10q26, we previously reported the amplification of genes encoding FGF receptors, FGFRI/FLG and FGFR2/BEK, in about 12% of breast tumors. The PLAT gene, encoding the tissue-type plasminogen activator, is also located close to or within the 8p12 region. In the present study, we show that both FGFRI and PLAT can be amplified in breast as well as ovarian carcinomas. FGFRI amplification was detected in 14.5% of breast and 7.8% of ovarian tumors, whereas PLAT was found to be amplified in 15.6% and 19.4% of the tumors, respectively. Each gene could be amplified independently of the other. These data raised the question of which gene is selected for amplification at 8p12. In most cases, the levels of expression of FGFRI and PLAT in breast tumors were comparable to their level of expression in normal mammary tissue. However, FGFRI was expressed above the normal level in a certain number of cases. This gene could be a good candidate as "driver" of the 8p12 amplification, but it cannot account for all complex molecular events taking place in this region.
在人类乳腺癌中发现几个染色体区域持续扩增。对于其中两个区域，即8p12和10q26，我们之前报道过在约12%的乳腺肿瘤中编码FGF受体的基因FGFRI/FLG和FGFR2/BEK发生了扩增。编码组织型纤溶酶原激活剂的PLAT基因也位于8p12区域附近或该区域内。在本研究中，我们发现FGFRI和PLAT在乳腺癌以及卵巢癌中均可发生扩增。在14.5%的乳腺肿瘤和7.8%的卵巢肿瘤中检测到FGFRI扩增，而PLAT分别在15.6%和19.4%的肿瘤中被发现发生扩增。每个基因的扩增可相互独立发生。这些数据提出了在8p12区域选择哪个基因进行扩增的问题。在大多数情况下，乳腺肿瘤中FGFRI和PLAT的表达水平与其在正常乳腺组织中的表达水平相当。然而，在某些病例中FGFRI的表达高于正常水平。该基因可能是8p12扩增“驱动因素”的一个良好候选者，但它无法解释该区域发生的所有复杂分子事件。
